Animal studies support inverse associations between FGF-23 levels and iron availability and erythropoietic activity [55, 56] and clinical, prospective trials have coupled total FGF-23 levels to the risk of incident anemia [57, 58]. This evidence concerns the gene FGF23 and anemia (phenotype).